International Society for the Study of Women's Sexual Health

ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   0 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   112 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

ISSWSH Sexual Pain Course 2020
April 17-18, 2020 112 days left
Georgetown University Medical Center, Medical and Dental Building, Washington, DC, USA

ISSWSH Annual Meeting 2021
March 4-7, 2021   476 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

@StephFaubionMD and Management of Genitourinary Syndrome of Menopause in Female Cancer Patients: A Focus on Vaginal… https://t.co/ydvLaADZ2V ISSWSH
Retrospective chart review shows that patients with vulvodynia do NOT have higher rates of infertility treatment co… https://t.co/Ri5nVIzNL9 ISSWSH
One of the biggest warnings when using Addyi for female HSDD is hypotension and syncope with alcohol consumption.… https://t.co/UNxsJIzI1J ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!